UPDATE: Morgan Stanley Reiterates On Abbott Laboratories As Growth and Margins Are Set To Continue

In a report published Thursday, Morgan Stanley analyst David R. Lewis reiterated an Overweight rating on Abbott Laboratories ABT, and raised the price target from $45.00 to $48.00. In the report, Morgan Stanley noted, “Abbott delivered a solid 2Q given growth inflection and margin expansion, which should continue. Capital deployment to drive growth (ex Nutritional and EPD) remains a catalyst. We raise PT to $48 given sales and margin momentum and SOTP multiple expansion for EPD pending sale of DM business.” Abbott Laboratories closed on Wednesday at $41.05.